Topic summary

Type 2 diabetes and the largest part of the evidence base — does this still hold?

Clinical › Comorbidities MASH / hepatic steatosis chronic kidney disease PCOS obstructive sleep apnoea type 2 diabetes Solved Wiki

This is a generated summary. It shows the 5 most-liked posts from a topic of 26, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

NorringtonTL3Regular23 Sep 2024#1

Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by np_gilmore on 18 Sep 2025.

2 Dec 2024 — mira.patel: Replaced an unsourced figure with the published one and cited it.
3 Jan 2025 — n.rowntree: Removed a claim that the cited source did not support.
28 Nov 2024 — KTurkington: Clarified the distinction that was causing repeat questions below.
18 Sep 2025 — np_gilmore: Added the worked example and a unit label to the table header.

Editors: mira.patel, n.rowntree, KTurkington, np_gilmore

Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below.

Asking about a population rather than about a person.

The published trials in this class mostly enrolled a fairly specific group, and the questions here frequently come from people well outside it. I would like to understand what the honest position is when someone falls outside the studied population: not "it is fine" and not "there is no data", but what the reasoning actually looks like.

42 likes 22mo

LJankowiakTL3Regular26 Sep 2024#5

Cardiovascular disease: several compounds have cardiovascular outcome trials. SELECT was in people without diabetes; SUSTAIN 6 was in high-risk diabetes. Absolute benefit is largest in high-risk people.

30 likes 22mo

integrator_traceTL2Member Solution29 Sep 2024#9

s.lundgren, post #6: For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct drug effect is not resolved by the trial.

7 likes in reply to #6 22mo

n.bridgewaterTL2Member1 Oct 2024 · edited#13

This follows post #10 rather than contradicting it.

Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and cardiovascular benefit evidence is separate from the glycaemic benefit evidence.

32 likes 22mo

DKwiatkowskiTL3Regular6 Oct 2024#23

PCOS and metabolic overlap: polycystic ovary syndrome has metabolic overlap with obesity and insulin resistance. Data on compounds in this class in PCOS specifically is thin; most discussion is by mechanism.

27 likes 22mo

Read the full topic (26 posts)

This topic was referenced in

About the Comorbidities categoryClinical › Comorbidities · 4 replies
Hepatic steatosis: what the MASH trial evidence supportsClinical › Comorbidities · 83 replies
Gallbladder disease risk with rapid weight lossClinical › Comorbidities · 63 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Gastro-oesophageal reflux: improving or worsening? Clinical › Comorbidities PCOS obstructive sleep apnoea MASH / hepatic steatosis chronic kidney disease Solved The question in the title: Gastro-oesophageal reflux: improving or worsening? I will give what I have already checked below so nobody repeats it. Asking about a population rather than about a person. The…	+54	58	8.2k	1mo
About the Comorbidities category Clinical › Comorbidities type 2 diabetes chronic kidney disease MASH / hepatic steatosis Pinned Wiki Type 2 diabetes, hepatic steatosis, sleep apnoea, cardiovascular and renal disease. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…		4	16k	12h
Hypertension improvement and when medication needs revisiting Clinical › Comorbidities type 2 diabetes MASH / hepatic steatosis chronic kidney disease Closed Hypertension improvement and when medication needs revisiting Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…	+74	79	1.1k	10mo
Hepatic steatosis: what the MASH trial evidence supports — one year on Clinical › Comorbidities MASH / hepatic steatosis obstructive sleep apnoea chronic kidney disease blood pressure Solved On the subject in the title: Hepatic steatosis: what the MASH trial evidence supports — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…		2	4.1k	6mo
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class Clinical › Comorbidities type 2 diabetes obstructive sleep apnoea MASH / hepatic steatosis chronic kidney disease Second pass at: Obstructive sleep apnoea and a hard endpoint in this class — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The…		2	726	14mo

Related topics — sharing the tags MASH / hepatic steatosis, chronic kidney disease, PCOS

Topic	Participants	Replies	Views	Activity
Chronic kidney disease and the FLOW result — a second dataset Clinical › Comorbidities MASH / hepatic steatosis blood pressure type 2 diabetes Chronic kidney disease and the FLOW result — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. General question, not a request for advice about my own care —…		2	2.3k	20mo
Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide semaglutide SELECT trial randomised trial effect size Solved The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med ,…	+73	79	2k	4mo
The C-cell question: rodent findings and their human context Compounds › Semaglutide STEP programme type 2 diabetes effect size Closed Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a…	+41	45	24k	12mo
Insomnia at a dose step: reported experiences Wellbeing › Sleep fatigue obstructive sleep apnoea heart rate Solved On the subject in the title: Insomnia at a dose step: reported experiences Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference and I…	+20	24	18k	8mo
Hypertension improvement and when medication needs revisiting — a second dataset Clinical › Comorbidities blood pressure type 2 diabetes obstructive sleep apnoea MASH / hepatic steatosis Posting this under the heading it deserves: Hypertension improvement and when medication needs revisiting — a second dataset Everything below is what sits behind that. General question, not a request for…	+126	133	22k	21mo